Onco Actu du 11 septembre 2015

	1. Biologie
New Study Reveals Genomic Architecture of EGFR Mutations in Lung Cancer [IASLC] His team undertook a study performing whole exome and RNA-sequencing to determine genomic architecture of treatment naïve EGFR mutant lung cancers, (N=9, 47 sectors), as well as to elucidate mechanisms of resistance from analysis from a series TKI resistant biopsies.
	3.1 Tabac
Smokers who switch to e-cigarettes may breathe fewer toxins [Reuters] The 17 participants who swapped some regular cigarettes for the electronic version had a 52 percent decline in carbon monoxide exposure and a 60 percent decline for acrolein, according to the study published in Cancer Prevention Research.
	4. Dépistage, diagnostic et pronostic
How to light up a tumour [The Guardian] For decades, brain surgeons have struggled to identify cancerous tissue precisely. Could one of the world’s most deadly scorpions come to their aid?
	4.12 Biopsies liquides
Startup claims its test finds cancer early, but where’s the evidence? [The Verge] 'There is no peer-reviewed data to support their tests or technical approaches'.
Pathway launches 'liquid biopsy' to find cancer in healthy people [Reuters] Several oncology experts said liquid biopsy tests like Pathway's, while exciting, still require large clinical studies proving they help people beat cancer through early detection. Doctors will also need a clear assessment of their accuracy.
Why You Shouldn’t Bother with a $699 Cancer Test [MIT Technology Review] Catch cancer early for just $699? That is the pitch by Pathway Genomics, a diagnostic company in San Diego that began marketing a blood test to consumers today that it says can detect DNA mutations harbored by unseen cancer cells in your body.
	5. Traitements
Cancer drug produced in common plant [Scope Blog] Sattely said this is really a first step. Ultimately she’d like to get those same enzymes into yeast, which can produce high volumes of drugs in big laboratory vats.
Tiny 'cancer trap' could stop cancer spread [NHS Choices] Though the implant showed potential, we don't know it would work the same way in people. Even in mice, the implant didn't actually prevent metastases. The cancer still spread to other organs – the tumour burden was just less than when the implant was used.
	5.2 Pharma
Clovis leaps as AstraZeneca's AZD9291 disappoints on lung cancer [FierceBiotech] The result--based on preliminary data that could yet change--fell short of the advantage that some analysts were looking for to keep competition from Clovis's rociletinib (CO-1686) at bay.
	5.2.1 Pharma - Partenariats
Fishing for cancer cures: our new Cancer Research UK-MedImmune Alliance Laboratory [Cancer Research UK] This initial fishing trip pulls out many different phages, each making a different antibody that recognises the target. The next challenge is to find the one with that sticks to its target the strongest – meaning that it’s likely to be a potent and effective drug.
Cancer Research UK and MedImmune launch ground-breaking biotherapeutics research centre in Cambridge [Cancer Research UK] The alliance will bring together MedImmune’s world-class human antibody phage display libraries and protein-engineering expertise with Cancer Research UK’s cancer biology expertise.
	6.4 Médico-éco
IBA sees barriers falling as proton beams tested in more cancers [Reuters] Belgium's Ion Beam Applications (IBA), which has a market share of around 50 percent, has a growing pipeline of potential proton therapy business worth more than 1 billion euros ($1.1 billion), its finance chief Jean-Marc Bothy said.
	6.7 DMP, Big Data & applis
IBM Watson Health Cloud Capabilities Expand [IBM] IBM Watson Care Manager is a population health solution that uniquely integrates capabilities from Watson Health, Apple's HealthKit and ResearchKit, a software framework designed by Apple to make it easy for researchers to conduct studies using an iPhone. It allows medical professionals’ to factor a broad range of determinants into a personalized patient engagement program, with the intent to vastly improve individual health outcomes.
	6.9 Controverses
Selection panels, follow the “rule of thirds” [Phosphenes] Over the past decade or so, I have been part of quite a few grant panels, for national and international funding agencies. Each time, the funding agency felt compelled to reinvent all the procedures from scratch, and ignore whatever experience has been gained from thousands of such exercises in the past.